Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 8341-8350 Newer>

Pharmaceutical Executive June 1, 2012 Amy Smith	Marketing: Medical Devices vs. Pharma Understanding the differences between drug and device marketing can make or break the brand's promotional activities.
Pharmaceutical Executive June 1, 2012	Europe Responds to Medical Device 'Crisis' A recent medical device controversy in France has pushed European health ministers to agree on a crisis management program for the troubled sector.
Pharmaceutical Executive June 1, 2012 Ben Comer	Disruption in the C-Suite Clayton Christensen, author of "The Innovator's Dilemma," offers to collaborate with pharma CEOs on solutions to the strategic impasse around flagging drug productivity.
Pharmaceutical Executive June 1, 2012 Alex Gasik	ACOs are Here to Stay, Even if the ACA is Not No matter how the Supreme Court rules on healthcare reform, the accountable care model will stick around. To play ball with Accountable Care Organizations, drug companies will need to throw a different pitch.
Pharmaceutical Executive June 1, 2012 Jill Wechsler	Innovation and Collaboration A rash of "pro-innovative" approaches for testing and regulating medical products offer ways to speed more new products to market.
Pharmaceutical Executive June 1, 2012 William Looney	From the Editor:The Connections Game As the old Broadway song goes, June is busting out all over, and true to the season this month's issue stretches the seams with content that ranges from the sublime to the ridiculous.
Chemistry World June 17, 2012 Andrew Turley	Lundbeck to lose 600 jobs The Danish company says it must cut jobs 'to mitigate increased pressure from healthcare reforms, generic competition and uncertainty regarding pricing and reimbursement in Europe'.
Chemistry World June 14, 2012 Andrew Turley	Good signs for Merck & Co insomnia pill In Phase III trials, insomnia drug candidate suvorexant performed well, reducing the time patients needed to fall asleep and increasing the total time sleeping, with some patients benefitting from the very first night of treatment.
Chemistry World June 12, 2012 Nina Notman	Three pronged approach puts brakes on US breast cancer The US Food and Drug Administration (FDA) has approved the use of anti-HER2 therapy Perjeta (pertuzumab) to treat patients with previously untreated HER2-positive metastatic breast cancer.
Chemistry World June 12, 2012 Nina Notman	Pfizer to spin off animal health business It has been announced that preparations are underway to file for a potential stock market launch of the new firm. The standalone company name -- Zoetis -- was announced at the same time.
<Older 8341-8350 Newer> Return to current articles.